NCT05830760

Expression of Sodium-glucose Co-transporter 2 in Human Heart

Expression of Sodium Glucose Co-transporter2 in Myocardium From Patients With Aortic Valve Stenosis and With/Without Diastolic Heart Failure

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University Hospital, Strasbourg, France · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to evaluate the expression of Sodium Glucose Co-transporter 2 (SGLT2) in myocardium from patients with aortic stenosis. 2 groups of patients will be defined: Group A with diastolic heart failure and Group B without heart failure. The expression of SGLT2 will be measured on small myocardium specimens harvested during aortic valve replacement operation. This study should allow us to better understand the effect of glifozines in human heart failure.

Conditions

• Aortic Valve Stenosis

Interventions

Type	Name	Description
BIOLOGICAL	Myocardium biopsy	The expression of SGLT2 on small myocardium specimens harvested during aortic valve replacement operation in patients with aortic stenosis

Timeline

• Start date: 2023-06-01
• Primary completion: 2025-10-01
• Completion: 2025-10-01
• First posted: 2023-04-26
• Last updated: 2025-12-23

Locations

1 site across 1 country: France